TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Behavioral intervention at Kindergarten setting aiming at increased fruit and vegetable consumption, decreased intake of high energy foods, snacks, sweets, increased intake of water/low energy drinks, decreased intake of high energy drinks. Physical activity should be more than 1 hour/day and TV/media consumption less than 1 hour/day.

Main questions are:

Do children differ in intervention and control kindergartens according to their nutrition behaviour? Do children in the intervention kindergartens have a higher physical training than such in the control kindergartens? Data were collected with a standardised questionnaire.

Do children differ in intervention and control kindergartens according to their body mass index?


Options:
A: Intervention Type: BEHAVIORAL; Name: attitude change; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: adiposity prevention program; Assigned to Arm(s): N/A
B: Arm Label: Communications; Type: EXPERIMENTAL; Interventions: Other: Communications | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pricing; Type: EXPERIMENTAL; Interventions: Other: Pricing | Arm Label: Combined (Communications & Pricing); Type: EXPERIMENTAL; Interventions: Other: Combined (Communications & Pricing) | Intervention Type: OTHER; Name: Communications; Assigned to Arm(s): Communications | Intervention Type: OTHER; Name: Pricing; Assigned to Arm(s): Pricing | Intervention Type: OTHER; Name: Combined (Communications & Pricing); Assigned to Arm(s): Combined (Communications & Pricing)
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Primary (Environmental) Weight Gain Prevention | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: Primary (Environmental) Weight Gain Prevention, Behavioral: Secondary (Behavioral) Weight Gain Prevention | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Primary (Environmental) Weight Gain Prevention; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: BEHAVIORAL; Name: Secondary (Behavioral) Weight Gain Prevention; Assigned to Arm(s): Arm 2 | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Arm 3
D: Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Behavioral intervention at Kindergarten setting aiming at increased fruit and vegetable consumption, decreased intake of high energy foods, snacks, sweets, increased intake of water/low energy drinks, decreased intake of high energy drinks. Physical activity should be more than 1 hour/day and TV/media consumption less than 1 hour/day.

Main questions are:

Do children differ in intervention and control kindergartens according to their nutrition behaviour? Do children in the intervention kindergartens have a higher physical training than such in the control kindergartens? Data were collected with a standardised questionnaire.

Do children differ in intervention and control kindergartens according to their body mass index?


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Primary (Environmental) Weight Gain Prevention | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: Primary (Environmental) Weight Gain Prevention, Behavioral: Secondary (Behavioral) Weight Gain Prevention | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Primary (Environmental) Weight Gain Prevention; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: BEHAVIORAL; Name: Secondary (Behavioral) Weight Gain Prevention; Assigned to Arm(s): Arm 2 | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Arm 3
B: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Go NAP SACC | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Go NAP SACC; Assigned to Arm(s): Intervention group
C: Arm Label: Eating and physical activity counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Eating and physical activity counseling | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Eating and physical activity counseling; Assigned to Arm(s): Eating and physical activity counseling
D: Intervention Type: BEHAVIORAL; Name: attitude change; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: adiposity prevention program; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TRUST: Lumos-T Safely RedUceS RouTine Office Device Follow-up
Brief Summary: This study is a multi-center, prospective and randomized trial. The primary objective of this study is to demonstrate that the use of the BIOTRONIK Home Monitoring system (HM) can safely reduce the number of regularly scheduled office follow-up visits, compared to the conventional method of implantable cardioverter defibrillator (ICD) follow-up.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: telemedicine | Intervention Type: OTHER; Name: telemedicine; Assigned to Arm(s): 2
B: Arm Label: Home Monitoring; Type: ACTIVE_COMPARATOR; Interventions: Other: Home Monitoring | Arm Label: In-Office Conventional Follow-up; Type: OTHER; Interventions: Other: In-Office Conventional Follow-up | Intervention Type: OTHER; Name: Home Monitoring; Assigned to Arm(s): Home Monitoring | Intervention Type: OTHER; Name: In-Office Conventional Follow-up; Assigned to Arm(s): In-Office Conventional Follow-up
C: N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-Directed Weight Loss Program | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Call-Center Directed (CCD) Weight Loss Program | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: In-Person Directed (IPD) Weight Loss Program | Intervention Type: BEHAVIORAL; Name: Call-Center Directed (CCD) Weight Loss Program; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: In-Person Directed (IPD) Weight Loss Program; Assigned to Arm(s): 3 | Intervention Type: BEHAVIORAL; Name: Self-Directed Weight Loss Program; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Testing Screening Formats for Indicator-Based and Universal Screening Measurements in the Identification of Woman Abuse.
Brief Summary: Recent reviews have identified the need for additional high quality exploratory and evaluative research to understand 1) the actual impact on all women of instituting mass screening procedures versus using indicator-based approaches to identifying woman abuse and 2) the extent to which early identification through screening -- either universal or indicator-based is effective in preventing or ameliorating important outcomes. This is a critical first step in developing a larger randomized controlled trial (RCT) which examines the effectiveness of screening in preventing woman abuse, improving quality of life and other associated outcomes. This study prepares for the RCT by testing the optimal method of administration for the two screening instruments that will be used in the RCT. The administration formats are: computer-based screen, paper and pencil screen and face-to-face screen. They study will also determine recruitment rates.


Options:
A: Intervention Type: BEHAVIORAL; Name: Screening via pen and paper; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Screening via audiotape; Assigned to Arm(s): N/A
B: Arm Label: advocacy intervention; Type: EXPERIMENTAL; Interventions: Behavioral: advocacy intervention | Arm Label: Usual community services; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: usual community services | Intervention Type: BEHAVIORAL; Name: advocacy intervention; Assigned to Arm(s): advocacy intervention | Intervention Type: BEHAVIORAL; Name: usual community services; Assigned to Arm(s): Usual community services
C: Intervention Type: PROCEDURE; Name: Woman Abuse Screening Tool; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Partner Violence Screen; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Computerized screening; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Face to face screening; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Written screening on forms; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Prompting (survey instrument/resources list) (behavior); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)
Brief Summary: This study will provide preliminary data on the dose and dose interval related effects of intravitreally administered Avastin on retinal thickness and visual acuity in subjects with Diabetic Macular Edema (DME) to aid in planning a phase 3 trial.

In addition, this study will provide preliminary data on the safety of intravitreally administered Avastin in subjects with DME.


Options:
A: Arm Label: Dexamethasone 700 μg; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Dexamethasone 350 μg; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Other: Sham | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone 350 μg, Dexamethasone 700 μg | Intervention Type: OTHER; Name: Sham; Assigned to Arm(s): Sham
B: Intervention Type: DRUG; Name: Triamcinolone acetate; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laser Photocoagulation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Intervention Type: PROCEDURE; Name: Laser Photocoagulation; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 5
D: Arm Label: 0.5mg Ranibizumab plus laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab + laser | Arm Label: 0.5 mg Ranibizumab plus deferred laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab + deferred laser | Arm Label: 4 mg Triamcinolone plus laser; Type: EXPERIMENTAL; Interventions: Drug: Triamcinolone Acetonide + laser | Arm Label: Sham plus laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sham injection + laser | Intervention Type: DRUG; Name: Triamcinolone Acetonide + laser; Assigned to Arm(s): 4 mg Triamcinolone plus laser | Intervention Type: DRUG; Name: Ranibizumab + laser; Assigned to Arm(s): 0.5mg Ranibizumab plus laser | Intervention Type: DRUG; Name: Sham injection + laser; Assigned to Arm(s): Sham plus laser | Intervention Type: DRUG; Name: Ranibizumab + deferred laser; Assigned to Arm(s): 0.5 mg Ranibizumab plus deferred laser

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Large Scale Clinical Trial Testing the Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic Congestive Heart Failure
Brief Summary: INTRODUCTION While pharmacological treatments specifically targeted to the cardio-circulatory system have been largely investigated, scanty controlled data are available concerning the role of dietary and metabolic approaches in the management/outcome of patients with heart failure. A large scale, randomized, clinical trial is proposed to test the effects of (a) n-3 PUFA and (b) a lipid lowering agent on top of the best recommended treatments for heart failure.

STUDY DESIGN

The GISSI-HF is a prospective, multicenter, randomized, double blind, placebo controlled study, with randomized allocation of patients with a clinical diagnosis of heart failure to:

Randomization 1 (R1): n-3 PUFA 1 g daily vs corresponding placebo; Randomization 2 (R2): rosuvastatin 10 mg daily vs corresponding placebo.

OBJECTIVES OF THE STUDY PRIMARY OBJECTIVES

To demonstrate that, in patients with heart failure treated at the best of recommended therapies, long term administration of (a) n-3 PUFA, (b) rosuvastatin is more effective than the corresponding placebo in the reduction of:

* All-cause mortality
* All-cause mortality or hospitalizations for cardiovascular reason

OTHER END-POINT MEASURES OF EFFICACY

To assess that long term administration of (a) n-3 PUFA, (b) rosuvastatin is more effective than corresponding placebo in the reduction of:

* Cardiovascular mortality
* Cardiovascular mortality or hospitalizations for any reason
* Sudden cardiac death
* Hospitalizations for any reason
* Hospitalizations for cardiovascular reasons
* Hospitalizations for congestive heart failure
* Myocardial infarction
* Stroke


Options:
A: Intervention Type: DRUG; Name: Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM); Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: n-3 PUFA | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: n-3 PUFA; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
C: Arm Label: Omega 3 recipient arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omega 3 Fish Oil supplements | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega 3 Fish Oil supplements; Assigned to Arm(s): Omega 3 recipient arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Fish oil; Type: EXPERIMENTAL; Interventions: Drug: Fish oil | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Fish oil; Assigned to Arm(s): Fish oil

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Large Scale Clinical Trial Testing the Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic Congestive Heart Failure
Brief Summary: INTRODUCTION While pharmacological treatments specifically targeted to the cardio-circulatory system have been largely investigated, scanty controlled data are available concerning the role of dietary and metabolic approaches in the management/outcome of patients with heart failure. A large scale, randomized, clinical trial is proposed to test the effects of (a) n-3 PUFA and (b) a lipid lowering agent on top of the best recommended treatments for heart failure.

STUDY DESIGN

The GISSI-HF is a prospective, multicenter, randomized, double blind, placebo controlled study, with randomized allocation of patients with a clinical diagnosis of heart failure to:

Randomization 1 (R1): n-3 PUFA 1 g daily vs corresponding placebo; Randomization 2 (R2): rosuvastatin 10 mg daily vs corresponding placebo.

OBJECTIVES OF THE STUDY PRIMARY OBJECTIVES

To demonstrate that, in patients with heart failure treated at the best of recommended therapies, long term administration of (a) n-3 PUFA, (b) rosuvastatin is more effective than the corresponding placebo in the reduction of:

* All-cause mortality
* All-cause mortality or hospitalizations for cardiovascular reason

OTHER END-POINT MEASURES OF EFFICACY

To assess that long term administration of (a) n-3 PUFA, (b) rosuvastatin is more effective than corresponding placebo in the reduction of:

* Cardiovascular mortality
* Cardiovascular mortality or hospitalizations for any reason
* Sudden cardiac death
* Hospitalizations for any reason
* Hospitalizations for cardiovascular reasons
* Hospitalizations for congestive heart failure
* Myocardial infarction
* Stroke


Options:
A: Arm Label: statin; Type: EXPERIMENTAL; Interventions: Drug: atorvastatin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): statin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: n-3 PUFA | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: n-3 PUFA; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
C: Intervention Type: DRUG; Name: CRESTOR; Assigned to Arm(s): N/A
D: Arm Label: treatment; Type: EXPERIMENTAL; Interventions: Drug: Simvastatin | Arm Label: untreated; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Dose Ranging Study With the Beta-3 Agonist YM178 in Patients With Symptomatic Overactive Bladder
Brief Summary: The study will examine which dose of YM178 is best in terms of efficacy, safety and tolerability compared to placebo and compared to tolterodine, a marketed product.


Options:
A: Arm Label: YM178 group; Type: EXPERIMENTAL; Interventions: Drug: YM178 | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: tolterodine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: tolterodine | Intervention Type: DRUG; Name: YM178; Assigned to Arm(s): YM178 group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo group | Intervention Type: DRUG; Name: tolterodine; Assigned to Arm(s): tolterodine group
B: Arm Label: Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Solifenacin Succinate; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin Succinate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Solifenacin Succinate; Assigned to Arm(s): Solifenacin Succinate
C: Intervention Type: DRUG; Name: YM178; Assigned to Arm(s): N/A
D: Arm Label: TROSPIUM CHLORIDE; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trospium Chloride | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trospium Chloride; Assigned to Arm(s): TROSPIUM CHLORIDE | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PLACEBO

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Brief Summary: The purpose of this study is to compare E7389 versus capecitabine in patients with locally advanced or metastatic breast cancer who are refractory to the most recent chemotherapy. This is an open-label, randomized, two-parallel arm study. Patients will be randomized to receive either E7389 or capecitabine on a one-to-one ratio.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Eribulin Mesylate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine | Intervention Type: DRUG; Name: Eribulin Mesylate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): 2
B: Arm Label: MBSR 6 Weeks Program; Type: EXPERIMENTAL; Interventions: Behavioral: MBSR 6 Weeks Program | Arm Label: Usual Care (UC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MBSR 6 Weeks Program; Assigned to Arm(s): MBSR 6 Weeks Program
C: Arm Label: MBSR; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-based stress reduction | Intervention Type: BEHAVIORAL; Name: Mindfulness-based stress reduction; Assigned to Arm(s): MBSR
D: Arm Label: MBSR self care program including weekly sessions; Type: EXPERIMENTAL; Interventions: Other: MBSR | Arm Label: MBSR self care program; Type: EXPERIMENTAL; Interventions: Other: MBSR | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: MBSR; Assigned to Arm(s): MBSR self care program, MBSR self care program including weekly sessions

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Network to Control Risk Factors After Acute Coronary Syndrome
Brief Summary: The purpose of this study is to determine whether the follow up of patients with acute coronary syndrome and modifiable cardiovascular risk factors is efficient based on outpatients visits in a House of Education, underlining the importance of nicotinic weaning, weight loss and physical activity practice.


Options:
A: Intervention Type: OTHER; Name: Peer Support; Assigned to Arm(s): N/A
B: Arm Label: Community-based nurse care management; Type: EXPERIMENTAL; Interventions: Other: Community-based nurse care management | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Community-based nurse care management; Assigned to Arm(s): Community-based nurse care management
C: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention Group | Intervention Type: BEHAVIORAL; Name: Intervention Group; Assigned to Arm(s): Intervention Group
D: Arm Label: conventional; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: structured; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: education | Intervention Type: BEHAVIORAL; Name: education; Assigned to Arm(s): structured

Answer: D